Bioiberica to be present at the DCAT Week in New York
- Ther Heparin Business Unit will attend this event, to be held on 14-17 March 2016
- DCAT Week is the most important event in the field of business development for the major pharmaceutical industry companies
Heparin Science, Bioiberica’s Business Unit dedicated to the research, development, production and marketing of heparin, will be present, as it is every year, at this important meeting, with the aim of making new strategic alliances and finding new business opportunities.
The format of DCAT Week makes it the ideal place for that, because it is not a trade fair, but a week of meetings (most of them pre-scheduled) between customers, suppliers and potential marketing partners.
In this regard, anyone interested in arranging a meeting with Bioiberica may do so through the following email: heparinscience@bioiberica.com
Bioiberica has specialized since 1975 in the production of heparin, becoming the world leader in the production of this anticoagulant and anti-thrombotic drug: one out of every five heparin doses administered in the world is developed and manufactured in Spain by Bioiberica.
Related News
A crucial initiative to prevent shortages of critical medicines in the European Union.
The 28th Symposium on Glycosaminoglycans, an internationally renowned scientific event focusing on glycosaminoglycans, will be sponsored by
- Bioiberica produces 20% of the world's Heparin API.
- Heparin saves around a hundred million lives every year.
- One out of every 5 doses of heparin administered in the world comes from Bioiberica.